Physician profile
David B Damrich
NPI 1124068119
$2,410.03
in general payments reported to CMS, 2019-2025
28 companies · $428 in 2025
The $428 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $692 · 2021: $333 · 2022: $187 · 2023: $235 · 2024: $223 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $579.36 | 2020 | |
| Abbvie INC. | $381.92 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $220.09 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $200.81 | 2022-2025 | |
| Amgen INC. | $170.00 | 2019-2023 | Prolia, Evenity |
| Hologic Sales and Service, LLC | $115.67 | 2021-2025 | Aptima, Fluent Fluid Management System, Novasure |
| Sumitomo Pharma America, INC. | $112.84 | 2024-2025 | Gemtesa, Myfembree |
| Sage Therapeutics, LLC | $86.23 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $52.44 | 2021 | |
| Coopersurgical, INC. | $52.27 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $51.18 | 2019-2020 | |
| Ethicon US, LLC | $51.10 | 2025 | Surgiflo Hemostatic Matrix, Enseal, Harmonic |
| Supernus Pharmaceuticals, INC. | $42.21 | 2025 | Qelbree |
| Mylan Pharmaceuticals INC. | $40.97 | 2020-2022 | |
| Shield Therapeutics INC | $37.16 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $23.91 | 2019 | |
| Novo Nordisk INC | $22.32 | 2019 | |
| Organon LLC | $19.05 | 2023 | Nexplanon |
| Agile Therapeutics, INC. | $18.87 | 2021 | |
| Exeltis, USA INC. | $18.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.08 | 2019 | |
| Minerva Surgical, INC | $16.19 | 2025 | |
| Millicent US INC | $15.86 | 2023 | Intrarosa |
| Therapeuticsmd, INC. | $13.60 | 2019 | |
| Boston Scientific Corporation | $13.20 | 2020 | |
| Becton, Dickinson and Company | $12.73 | 2023 | Bd Onclarity |
| Merck Sharp & Dohme LLC | $12.28 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Damrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.